Inspiration Biopharmaceuticals to Present at the UBS Global Life Sciences Conference
CAMBRIDGE, Mass., Sept. 13, 2012 /PRNewswire/ — Inspiration Biopharmaceuticals, Inc., an emerging biopharmaceutical company developing new treatment options for people with hemophilia, today announced that John P. Butler, Chief Executive Officer, will present at the UBS Global Life Sciences Conference on Thursday, September 20, 2012. The presentation will take place at 4:00 p.m. ET at the Grand Hyatt Hotel in New York.
About Inspiration Biopharmaceuticals
As the only biopharmaceutical company dedicated solely to hemophilia, Inspiration is committed to improving the care of people with this condition by broadening treatment choices, expanding global access to care and advancing innovative therapies. Founded by two families whose sons have hemophilia, Inspiration is inspired to make a difference in the lives of people impacted by hemophilia around the world. Inspiration’s lead product candidates are IB1001, an investigational intravenous recombinant factor IX being developed for the treatment of hemophilia B, and OBI-1, an investigational recombinant porcine factor VIII being developed for the treatment of serious bleeds in patients with congenital hemophilia A with inhibitors or acquired hemophilia A.
For more information about Inspiration Biopharmaceuticals, please visit www.inspirationbio.com.
Contacts: Media Investors Kate Lewis Gordon H. Busenbark Feinstein Kean Healthcare Senior Vice President, Chief Financial Officer Tel: +1-617-577-8110 Tel: +1-617-588-1802 Email: email@example.com
SOURCE Inspiration Biopharmaceuticals, Inc.